Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage
- PMID: 10913404
- DOI: 10.1086/313902
Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage
Abstract
Acinetobacter species are problematic nosocomial pathogens. In November 1997, pathogens isolated by microbiology laboratories were collected from 15 hospitals in Brooklyn, New York. Acinetobacter species accounted for 10% of gram-negative isolates. Only half of Acinetobacter species were susceptible to carbapenems; 11 hospitals had at least 1 isolate resistant to carbapenems. Other Acinetobacter susceptibility rates were as follows: polymyxin, 99%; amikacin, 87%; ampicillin/sulbactam, 47%; ceftazidime, 25%; and ciprofloxacin 23%. Overall, 10% were resistant to all commonly used antibiotics. Genetic analysis by use of pulsed-field gel electrophoresis of 12 carbapenem-resistant isolates revealed 4 strains that were recovered from >1 hospital, which suggests interinstitutional spread. Antibiotic usage data from 11 hospitals revealed that the use of third-generation cephalosporins was associated significantly with the percentage of carbapenem-resistant strains (P=.03). Resistant Acinetobacter species have become endemic in Brooklyn, New York. Citywide strategies that involve surveillance, infection-control practices, and the reduction of antibiotic usage may be necessary to control the spread of these pathogens.
Similar articles
-
Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City.Clin Infect Dis. 2003 Jul 15;37(2):214-20. doi: 10.1086/375821. Epub 2003 Jul 9. Clin Infect Dis. 2003. PMID: 12856214
-
Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.Arch Intern Med. 2005 Jun 27;165(12):1430-5. doi: 10.1001/archinte.165.12.1430. Arch Intern Med. 2005. PMID: 15983294
-
Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II.J Antimicrob Chemother. 2008 Sep;62(3):484-9. doi: 10.1093/jac/dkn205. Epub 2008 May 13. J Antimicrob Chemother. 2008. PMID: 18477708
-
OXA (beta)-lactamases in Acinetobacter: the story so far.J Antimicrob Chemother. 2006 Jan;57(1):1-3. doi: 10.1093/jac/dki425. Epub 2005 Dec 6. J Antimicrob Chemother. 2006. PMID: 16332731 Review.
-
The impact of carbapenemases on antimicrobial development and therapy.Curr Opin Investig Drugs. 2002 Feb;3(2):218-24. Curr Opin Investig Drugs. 2002. PMID: 12020049 Review.
Cited by
-
Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii.Antimicrob Agents Chemother. 2002 Jun;46(6):1946-52. doi: 10.1128/AAC.46.6.1946-1952.2002. Antimicrob Agents Chemother. 2002. PMID: 12019113 Free PMC article.
-
Multidrug-resistant Acinetobacter baumannii.Emerg Infect Dis. 2005 Jan;11(1):22-9. doi: 10.3201/eid1101.040001. Emerg Infect Dis. 2005. PMID: 15705318 Free PMC article.
-
The global epidemiology of carbapenem-resistant Acinetobacter baumannii.JAC Antimicrob Resist. 2025 Jul 29;7(4):dlaf134. doi: 10.1093/jacamr/dlaf134. eCollection 2025 Aug. JAC Antimicrob Resist. 2025. PMID: 40735512 Free PMC article. Review.
-
A new metric of antibiotic class resistance in gram-negative bacilli isolated from hospitalized children.Infect Control Hosp Epidemiol. 2012 Jun;33(6):602-7. doi: 10.1086/665709. Epub 2012 Apr 13. Infect Control Hosp Epidemiol. 2012. PMID: 22561716 Free PMC article.
-
Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria.BMC Infect Dis. 2005 Apr 8;5:24. doi: 10.1186/1471-2334-5-24. BMC Infect Dis. 2005. PMID: 15819983 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources